Persistence. It cannot be excluded that celecoxib is persistent, due to the lack of data.
Bioaccumulation. It cannot be excluded that celecoxib bioaccumulates, due to the lack of data.
Toxicity. It cannot be excluded that celecoxib is toxic, due to the lack of data.
Risk. The environmental risk is not considered to be that great from a Swedish perspective.
Information about the risk comes from the report by Goodpoint 2019. Environmental information is missing on fass.se (2023-03-16). It is voluntary for manufacturers to provide information about environmental impact on fass.se.
Scientific discussion for the approval of Onsenal (celecoxib)
Onsenal is no longer authorised. "This scientific discussion has been updated until 1 May 2004. No particular risks to the environment of celecoxib use in FAP (familial adenomatous polyposis, red note) can be foreseen." Comment: The PEC values used to calculate risk in the manufacturers' assessment reports are based on the estimated use of the medicinal product to which the assessment report relates, not all medicinal products containing the same active substance
Report Goodpoint 2019
Comparative assessment of environmental risk when using diclofenac, naproxen, ibuprofen, ketoprofen, etoricoxib, celecoxib and paracetamol from a Swedish perspective (Report Goodpoint 2019). From an environmental risk point of view, the exchange of diclofenac is recommended for any of the other investigated NSAIDs/analgesics. [...] Paracetamol is a very safe alternative from an environmental point of view. The others are also considered to pose low environmental risk, but slightly increased for ketoprofen. The risk factors for ketoprofen, naproxen, ibuprofen, celecoxib, etoricoxib and paracetamol are not considered so great that an exchange with another substance is recommended. Environmental measurements as well as efficacy studies of both celecoxib and etoricoxib are required."
Author: Health and Medical Care Administration, Region Stockholm